Powering Smart
Health with Your Blood

Blood2Power aims to revolutionize smart health by introducing the next generation of vascular prostheses.

Blood as Energy Source to Power Smart Cardiac Devices

Blood2Power aims to revolutionize smart health by introducing the next generation of vascular prostheses that can monitor their performance, enabling an early diagnosis of their failure, and allowing a medical intervention before the occurrence of a second cardiovascular event.

 

Quality of life for millions

The Blood2Power ambition lies in leveraging collective expertise to address the alarming mortality rates linked to cardiovascular diseases. Through advanced technology and collaborative efforts, Blood2Power aims to revolutionize healthcare with continuous monitoring and innovative solutions. Envisioning a transformative impact on the economy and society, this project holds the potential to save lives and enhance the quality of life for millions.

 

 

Aims to synergize expertise

The Blood2Power consortium, led by project coordinator Inês Gonçalves, unites experts from four renowned institutions- i3S, UPORTO, TECNUN, and MUV-spanning three European countries to drive innovation in vascular medical devices. This international team assembles researchers with unique and complementary backgrounds in biomaterials, energy harvesting, electronics, and medicine. With a shared dedication, the consortium aims to synergize expertise and collaborative efforts, establishing a strong foundation for the success of this pioneering European initiative.

 
Monitoring Innovation Sensing
Powering Smart Health with Your Blood
Powering Smart Health with Your Blood

The Project

Problem

The major health threat of the 21st century is cardiovascular disease, killing one person every two seconds (18.6 million per year worldwide). The majority of cardiovascular diseases are linked to the constriction or blockage of blood vessels. Vascular grafts play a vital role in tackling these diseases by replacing or bypassing damaged vessels (3.6 million per year), particularly in the heart (coronary arteries) and legs (peripheral arteries)

Background

Unfortunately, vascular grafts face high failure rates of up to 50, primarily due to thrombosis and infection, which drastically result in deaths related to cardiovascular diseases. Ideally, one would be able to monitor the performance of vascular grafts and transfer data to initiate medical actions to avoid graft failure. 

Solution

The EU-funded Blood2Power project aims to contribute to finding a new power supply mechanism for powering the next-generation vascular graft, the iGraft. The objective is to develop triboelectric nanogenerators (TENGs), converting body mechanical energy into electrical energy. A miniaturised ultra-low energy consumption power management unit and wireless system will be coupled to the vascular graft, collecting and wirelessly transmitting signals to an external electronic device, such as a smartphone or watch

Consortium

Blood2Power assembles an international and multidisciplinary team comprising researchers from four institutions (i3S, UPORTO, TECNUN, and MUV) bridging three different countries. This collaborative alliance harnesses the complementary expertise essential for the success of the project.

Consortium

Blood2Power assembles an international and multidisciplinary team comprising researchers from four institutions (i3S, UPORTO, TECNUN, and MUV) bridging three different countries. This collaborative alliance harnesses the complementary expertise essential for the success of the project.

Contact us

Blood2Power Coordinator

Inês Gonçalves

Advanced Graphene Biomaterials Group

icastro@i3s.up.pt

Rua Alfredo Allen, 208

4200-135 Porto, Portugal

+351 226 074 900

This project has received funding from the European Union’s Horizon EIC Pathfinder Challenges 2022 under grant agreement no. 101115525. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.